outperform price
want
st guid omx time get on-board
thesi updat wowwhil arguabl expect high
print thought cover base organ
revenue bullish guid new restructur program
give om visibl within thought ceo bryan
hanson rosa commentari half knee
growth come rosa knee bullish context
commentari slightli less knee driven
rosa math think place rosa
system impress consid
year launch syk system year
launch highlight us dental print
come market commentari around commerci
invest pay suggest sustain second
guid organ came expect
point manag confid revenue acceler
lastli ice cake management put floor
om provid visibl high singl digit ep
growth trajectori frankli hard press find
neg print rais estim new
pt equat price-to-earnings dcf valuat
compel termin multipl impli tgr
reaffirm outperform rate
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
fx neg slightli posit
om
use financ rx invest
expect mm investment/rx en rout
focu set innov pipelin
spine cmf need work invest stabil busi
dental momentum begin show strength
hip grew line w/ market
gm benefit higher volum time cost
drove knee growth
continu increas invest commerci infrastructur
persona revis drive addit volum
rosa demand strong
underli knee growth crush well
placement better
margin expans linear
need msd growth remain top quartil perform lr
continu invest dedic channel still underway
busi unit reorg de-lay reduc redund improv margin via effici
warsaw fda observ manag
issu get resolv
volatil desir
offer complet beyond rosa spine
launch
spine/brain launch develop use system spine far
better posit go attract target
sport extrem focu area within set
regrett turnov come talent get upgrad zimmer global trend
robot mix cementless higher non-robot
valuat methodolog base mix discount cash flow analysi rel valuat multipl
upsid faster expect return full product suppli faster expect uptak new product includ cementless
revis could drive knee sale growth upper end mid singl digit faster expect adopt rosa
competit share gain market incumb downsid greater expect invest result margin contract
delay reach full product suppli limit organ sale growth joint reconstruct slower expect custom
sale forc recept post complet suppli issu
articl articl
time dissemin februari
analyst jon bristow vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
